JOBS Gets To Work On IPOs, Companies Cherry Pick Benefits
This article was originally published in The Pink Sheet Daily
The JOBS Act has made it easier for life sciences companies to file to go public and to communicate with potential investors. But the cost savings from reduced regulatory compliance has yet to be fully achieved.
You may also be interested in...
On The Road And Through The Window: Inside Three Biotech IPOs
Ophthotech, OncoMed, and bluebird bio are three of the dozens of biotechs that have made public debuts this year. Here’s how they did it, and the decisions they made to take advantage of being in the right place at the right time.
As Some New Listings Thrive, IPO Pipeline Burgeons
Encouraging results from some early 2013 offerings have led to four new filings in April. If the pattern holds, this year could be a better year for new listings than 2012.
Biopharma IPOs Start to Gear Up For 2013 After a Lull
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.